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ABSTRACT 
Background: Tau imaging using PET is a promising tool for the diagnosis and 
evaluation of tau-related neurodegenerative disorders, but the relationship 
among PET-detectable tau, neuroinflammation and neurodegeneration is not 
yet fully understood. We aimed to elucidate sequential changes in tau 
accumulation, neuroinflammation and brain atrophy by PET and MRI in a 
tauopathy mouse model.   
Methods: rTg4510 transgenic (tg) mice expressing P301L mutated tau and 
non-tg mice were examined with brain MRI and PET imaging (analyzed 
numbers: tg = 17, non-tg = 13; age 2.5~14 months). As PET probes, [11C]PBB3 
(Pyridinyl-Butadienyl-Benzothiazole 3) and [11C]AC-5216 were used to visualize 
tau pathology and 18-kDa translocator protein (TSPO) neuroinflammation. Tau 
pathology and microglia activation were subsequently analyzed by 
histochemistry.  
Results: PET studies revealed age-dependent increases in [11C]PBB3 and 
[11C]AC-5216 signals, which were correlated with age-dependent volume 
reduction in the forebrain on MRI. However, the increase in [11C]PBB3 signals 
reached a plateau at age 7 months, and therefore its significant correlation with 
[11C]AC-5216 disappeared after age 7 months. In contrast, [11C]AC-5216 
showed a strong correlation with both age and volume reduction until age 14 
months. Histochemical analyses confirmed the relevance of pathological tau 
accumulation and elevated TSPO immunoreactivity in putative microglia. 
Conclusion: Our results showed that tau accumulation is associated with 
neuroinflammation and brain atrophy in a tauopathy mouse model. The time-
course of the [11C]PBB3- and TSPO-PET finding suggests that tau deposition 
triggers progressive neuroinflammation, and the sequential changes can be 
evaluated in vivo in mouse brains. 
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Introduction 
Filamentous tau aggregates are the histopathological hallmark of a group of 
neurodegenerative disorders including Alzheimer’s disease (AD), progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD) and Pick’s disease 
(PiD), familial frontotemporal lobar degeneration (FTLD) with underlying tau 
pathology (FTLD-Tau) collectively referred to as tauopathies [1]. Since the 
pathogenesis of tau pathology is the stem of these disorders, in vivo 
visualization of tau pathology has the potential to enable an early diagnosis of 
tauopathy. Recent advances in positron emission tomography (PET) imaging for 
tauopathy allow us to noninvasively examine the state of tau protein in living 
human brains [2-7]. Among potential tau PET tracers, 11C-labeled 
phenyl/pyridinil-butadienyl-benzothiazoles/benzothiazolium 3 ([11C]PBB3), 
[18F]AV-1451 and [18F]THKs have been used for pre-clinical studies in human 
brain imaging [6-8]. Among these tracers, PBB3 compound, based on a phenyl 
/pyridinil-butadienyl-benzothiazoles /benzothiazolium (PBB) backbone 
compound, selectively binds to -pleated sheet structures such as 
neurofibrillary tangles (NFTs), neuropil threads (NTs) and diffuse plaques, 
although selective binding to NFTs is much higher than the binding to plaques 
[2]. Moreover, the binding affinity of PBB3 to discrete tau pathologies (e.g. 
NFTs, NTs, coiled bodies, tufted astrocytes, astrocytic plaques) in diverse 
tauopathies is higher than that of AV-1451, indicating the utility of PBB3 to 
capture wide-range tau pathologies [9]. 
Animal models mimicking salient aspects of diseases should be used for 
preclinical studies. Indeed, genetic mutations identified in familiar forms of 
disease have led to the recapitulation of underlying pathological processes in 
animal models. Moreover, conditional transgenic systems now provide powerful 
experimental tools for investigating the mechanisms of neurodegenerative 
diseases and evaluation of therapeutic interventions. Based on this system, 
researchers have developed the rTg4510 mouse line, thereby recapitulating 
some aspects of AD. The rTg4510 mouse line is a bigenic mouse model that 
permits the tetracycline-repressible overexpression of P301L mutant tau protein 
[10]. This P301L mutation was discovered in FTLD-Tau but not in AD [11]. 
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Expression of tau protein is controlled by the tetracycline transactivator (tTA) 
transgene under the Ca2+/calmodulin-dependent protein kinase II (CaMKII) 
promoter, which leads to tau expression in the forebrain of rTg4510 mice. 
Intracellular deposition of tau protein was pathologically detected in the cortico-
limbic area of rTg4510 mice, reflecting tauopathy with similarities to AD and 
they developed forebrain atrophy associated with aging [10, 12-16]. 
Immunohistochemical and biochemical examinations of postmortem rTg4510 
brains confirmed that the progression of NFT formation was drastically 
increased from 4 months to 6 months of age [12, 14, 15, 17]. Recently, 
advanced in vivo brain imaging techniques, including manganese-enhanced 
magnetic resonance imaging (MRI), arterial spin labeling, amide proton transfer 
imaging, diffusion tenser imaging and PET, have enabled us to visualize 
neuronal dysfunction and pathological tau accumulation in living rTg4510 mice 
[18-22].  
Mounting evidence suggests that NFT formation and neuroinflammation play an 
important role in the neuronal loss during neurodegenerative processes [23-25]. 
Notably, the immunosuppressive drug FK506 has attenuated the tau pathology 
and increased the lifespan of the tau model mouse, suggesting 
neuroinflammation as a causative factor for the development of tauopathy [26]. 
The mitochondrial 18-kDa translocator protein (TSPO) is upregulated in 
activated glia in central nervous system inflammatory diseases including AD 
[27], and several PET tracers (e.g., (R)-[11C]PK11195, [18F]DPA-714, 
[11C]PBR28, [18F]FEDAA1106) are available for assessing TSPO expression in 
vivo [28]. As for our PET studies with TSPO radioligands, [11C]DAA1106 and 
[11C]AC-5216, we have demonstrated that TSPO levels were increased not only 
in human AD [29], but also in the tauopathy model mouse [30], respectively. 
These results strongly support the hypothesis that neuroinflammation 
accelerates tau-induced neurodegenerative processes. However, the temporal 
sequence of microglial activation and NFT formation as well as brain atrophy 
remains unclear. 
In this study, in vivo visualization of tau pathology was conducted in rTg4510 
mice by utilizing [11C]PBB3 PET imaging. In parallel, the progression of brain 
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atrophy was cross-sectionally examined by T2-weighted MRI and microglial 
activation was investigated by [11C]AC-5216 PET. By combining non-invasive 
PET imaging data with structural neuroimaging data of living rTg4510 mice, the 
aim of the present study was to elucidate the spaciotemporal relationship 
among tau accumulation, neurodegeneration and neuroinflammation. 
 
Materials and Methods 
Mice 
rTg4510 mice, tau responder mice, and tTA activator mice were obtained from 
the University of Florida. A parental mutant tau responder line in the FVB/N 
strain (Clea Inc. Tokyo, Japan) and a tTA activator line in the 129+ter/SV strain 
(Clea Inc.) were generated and maintained, respectively. To make a tau 
responder line expressing the 4R0N isoform of human P301L mutant tau, cDNA 
was placed downstream of a tetracycline-operon-responder construct. The tTA 
activator system was placed downstream of CaMKII promoter. Hemizygous 
mice from each parental line were crossed to produce F1 offspring containing 
rTg4510 mice [10]. For the present study, non-transgenic (non-tg) mice without 
any exogenous gene expression were used as control mice. All procedures 
involving mice were performed with approval of the National Institute of 
Radiological Sciences Institutional Animal Care and Use Committees. 
 
MRI experiments 
Twenty-six mice were scanned at age 2.5-4 months (n=4 rTg4510, n=3 non-tg), 
7 months (n=3 rTg4510), 10-11 months (n=5 rTg4510), 12-14 months (n=5 
rTg4510, n=6 non-tg). All MRI experiments were performed on a 7.0T horizontal 
MRI scanner (Magnet: Kobelco and JASTEC, Japan; Console: Bruker Biospin, 
Germany) with a volume coil for transmission (Bruker Biospin) and a 2-ch 
phased array surface coil for reception (Rapid Biomedical, Germany). The mice 
were initially anesthetized with 3.0% isoflurane (Escain, Mylan Japan, Japan), 
and then anesthetized with 1.5 ~ 2.0% isoflurane and 1:5 oxygen/ room-air 
mixture during the MRI experiments. Rectal temperature was continuously 
monitored by optical fiber thermometer (FOT-M, FISO, Canada) and maintained 
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at 36.5±0.5˚C using a heating pad (Rapid Biomedical) and warm air. The first 
imaging slices were carefully set at the rhinal fissure with reference to the 
mouse brain atlas (Paxinos and Franklin, 2004). 
T2-weighted MRI: Transaxial T2-weighted fast spin-echo MR images were 
acquired using a rapid acquisition with relaxation enhancement (RARE) 
sequence in the same slice position as the T1-weighted MRI. The imaging 
parameters were as follows: TR / effective TE = 4,200 / 36 ms, Fat-Sup = on, 
NA = 4, RARE factor = 8, number of slices = 13, and scan time = 6 min 43 s. 
Frequency selective saturation pulses and crusher magnetic field gradients 
were used for fat suppression. 
 
In vivo PET imaging of mice 
PET scans were performed using a microPET Focus 220 animal scanner 
(Siemens Medical Solutions, Malvern, PA) immediately after intravenous 
injection of [11C]PBB3 or [11C]AC-5216. MicroPET Focus 220 is designed for 
rodents and small monkeys, providing 95 transaxial planes 0.815 mm (center-
to-center) apart, a 19.0-cm transaxial field-of-view (FOV), and a 7.6-cm axial 
FOV [31]. Radiosyntheses of [11C]PBB3 and [11C]AC-5216 were described in 
previous reports [2, 30, 32, 33]. Before PET measurements, a 31-gauge needle 
with catheter was inserted into the mouse tail vein for injection of [11C]PBB3 
(35.4±8.4 MBq, specific radioactivity was 79.4±9.9 GBq/ mol at injection) and 
[11C]AC-5216 (36.2±3.1 MBq, specific radioactivity was 265.6±60.8 GBq/ mol 
at injection). After a transmission scan for attenuation correction, a bolus of 
each ligand was injected, and an emission scan in 3D list mode was carried out 
for 60 or 90 min, respectively. All list-mode data were sorted into 3D sinograms, 
and were then Fourier-rebinned into 2D sinograms (60 min frames: 1 min x 10, 
5 min x 6, 10 min x 2. 90 min frames: 1 min x 4, 2 min x 8, 5 min x 14). Images 
were reconstructed with filtered back projection using a Hanning filter with a 
Nyquist cutoff of 0.5 cycle/pixel.  
 
Image analysis 
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To define anatomical regions of interest (ROIs), manual segmentation was 
performed on the T2-weighted MRI in a slice by slice fashion, by three 
experienced investigators using PMOD® software (ver 3.6, PMOD Technologies 
Ltd, Zurich, Switzerland). To avoid bias, manual tracing was performed without 
knowing age and genotype. Brain contours were double-checked by a single 
investigator to finalize the registration of ROIs. For co-registration with PET 
images, anatomical ROIs were manually defined on a part of cerebral cortices 
and dorsal hippocampi (labeled as forebrain in Fig.1). Regional radioactivities of 
[11C]PBB3 and [11C]AC-5216 were calculated as standardized uptake value 
[SUV = injected dose per tissue volume x body weight (g)] and the value of area 
under the curve (AUC) of the time-activity curves (TAC) in each region from 2 to 
30, or 0 to 90 min, respectively. The accumulations of radioligands of [11C]PBB3 
and [11C]AC-5216 were estimated by the ratios of AUC values in the forebrain to 
cerebellum from 0 to 60, or 0 to 90 min, respectively.  
 
Fluorescence staining 
In vitro fluorescence staining of mouse brain tissues was performed with PBB3 
(8-month-old rTg4510, n=2; 10-month-old rTg4510, n=2; 11-month-old rTg4510, 
n=3; 14-month-old rTg4510, n=1; 8-11-month-old non-transgenic mice, n=4; 
mouse IDs are listed in Table 1). The fluorescence ligand was dissolved in 50% 
ethanol. Deparaffinized sections were incubated with 56.5 M of PBB3 for 30 
min at 25ºC, followed by washing with 25% ethanol for 5 min. After mounting in 
non-fluorescent mounting solution (VECTASHIELD, Vector Laboratory, 
Burlingame, CA), images of fluorescence signals were captured with a Leica 
microscope (DM4000, Leica, Wetzlar, Germany) equipped with a color digital 
camera. PBB3-positive cells were manually counted in the field (0.3 mm x 0.4 
mm size) of captured images, and then the number of cells was averaged from 
5 fields of each section. For immunohistochemistry, PBB3-stained sections 
were autoclaved for antigen retrieval. After blocking with TNB blocking solution 
(PerkinElmer, Waltham, MA), sections were incubated with AT8 (mouse 
monoclonal, 1:500; Thermo Fisher Scientific, Waltham, MA). After incubated 
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with Alexa Fluor 555 goat anti-mouse IgG antibody (1:500; Life Technologies, 
Carlsbad, CA), red fluorescence signals were captured with the same 
microscope. For co-labeling with AT8 and TSPO, or with TSPO and GFAP, 
serial sections were incubated with AT8 (1:500) and TSPO (rabbit monoclonal, 
1:1,000; Abcam, Cambridge, UK) antibodies, or with TSPO (1:1,000) and GFAP 
(rat monoclonal, 1:500; Zymed, San Francisco, CA) antibodies. For red 
fluorescence images, Alexa Fluor 555 goat anti-mouse IgG antibody (1:500) or 
Alexa Fluor 555 goat anti-rat IgG antibody (1:500) was used. For green 
fluorescence images, biotinylated goat anti-rabbit IgG (1:1,000; Santa Cruz, 
Dallas, TX) was used for secondary antibody, and immunoreactivity was then 
visualized using fluorescein-labeled tyramide signal amplification (TSA 
fluorescein system, PerkinElmer). For co-labeling with TSPO and Iba1 
antibodies, sections were first incubated with TSPO antibody (1:2,000) followed 
by incubating with biotinylated goat anti-rabbit IgG (1:1,000). After visualizing 
with TSA fluorescein, sections were incubated with Iba1 antibody (rabbit 
polyclonal, 1:250; Wako, Japan) and labeled with Alexa Fluor 555 goat anti- 
rabbit IgG antibody (1:500). For single labeling with Iba1 or TSPO, serial 
sections were incubated with Iba1 (1:1,000) or TSPO (1:1,000). Subsequently, 
sections were incubated with biotinylated goat anti-rabbit IgG (1:1,000), and 
then visualized using tetramethylrhodamine-labeled tyramide signal 
amplification (TSA tetramethylrhodamine system). Images were captured by 
fluorescence microscope (BZ-X700, Keyence, Japan). For image quantification 
of TSPO-positive signals, multiple images (3 x 4 images) were captured and 
stitched into a single image. The area of the TSPO-positive signal was extracted 
and quantified by BZ-X Analyzer (Keyence). TSPO-positive level was displayed 
as the signal ratio (%) to the total area (2-3 mm2 field of forebrain region from 
each section). 
 
Statistical analysis  
Statistical analyses were conducted using PRISM6 (GraphPad Software Inc., 
La Jolla, CA). Data were analyzed using Spearman's correlation coefficient or 
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nonparametric test for comparing two or more groups, unless otherwise noted. 
Statistically significance was determined by the p-value below 0.05. 
 
Results 
Progressive brain atrophy 
Mouse brain regional volume was measured by T2-weighted MRI. The five 
structures — cerebral cortex, hippocampus, striatum, cerebellum, and brain 
stem — were manually delineated and labeled (Fig.1). Consistent with previous 
reports [20, 34], volumetric analysis confirmed prominent brain regional 
atrophies in hippocampi, cerebral cortices and striata of rTg4510 mouse brains 
compared to non-tg mice (Fig. 2). In 7- to 14-month-old rTg4510 mice, volume 
reduction was evident in the cerebral cortex, hippocampus and striatum, 
whereas volumes in brain stem and cerebellum were intact (Fig. 2B, D-G). On 
the other hand, volumes of brain regions in 2.5-month-old non-tg mice were not 
significantly different from those in 12-14-month-old non-tg mice (Fig. 2B-G). 
Cerebral cortices of 7-, 10-11- and 12-14-month-old rTg4510 mice were 80%, 
53% and 50% of those of non-tg mice, respectively. Likewise, forebrains of 7-, 
10-11-, and 12-14-month-old rTg4510 mice were 72%, 58% and 51% of those 
of non-tg mice, respectively. Therefore, atrophy of the forebrain region 
progressed at a similar rate to cortical volume reduction (Fig. 2C). Although the 
expression of human tau and the accumulation of pathological tau in the 
cerebellum and brain stem of rTg4510 mice were sparse, these volumes in 12-
14-month-old rTg4510 mice were significantly lower than those in age-matched 
non-tg mice (brainstem: 90%, cerebellum: 90%)(Fig. 2E and G). These volume 
reductions were much smaller than those of the other brain regions (cerebral 
cortex: 50%, hippocampus: 51%, striatum: 53%)(Fig. 2B, D and F). 
Nevertheless, if tau pathology appeared in the cerebellum and brain stem of 12-
14-month-old rTg4510 mice, transmission of tau pathology from forebrain 
regions might be involved in the volume reductions in these brain regions. 
However, further investigation will be required to prove this hypothesis.  
 
[11C]PBB3-PET imaging of rTg4510 mice  
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[11C]PBB3-PET imaging was examined in 2.5-14-month-old rTg4510 mice, 
which are known to develop tau pathology mostly in the cerebral cortex and 
hippocampus. After intravenous administration of [11C]PBB3 into rTg4510 mice, 
unbound [11C]PBB3 was rapidly washed out from the brain, with a half-life of 
~10 min, and the radioactivity level reached equilibrium [2]. High [11C]PBB3 
binding was observed in the cerebral cortex and hippocampus, and lowest 
binding in the cerebellum of rTg4510 mice (Fig. 3A), while [11C]PBB3 signal in 
each brain region of non-tg mice was less than that in the cerebellum of 
rTg4510 mice (Fig. 3B). When the TAC of [11C]PBB3 signals in each brain 
region of 12-14-month-old rTg4510 mice (n=5) was compared with that in the 
same region of age-matched non-tg mice (n=6), significant difference was 
observed in the forebrain, cerebral cortex, hippocampus, and striatum, but not 
in the cerebellum and brain stem (Fig. 3C, 3D and supplemental Fig. 1). The 
AUC of TAC of [11C]PBB3 signals at 2-30 min in the forebrain of 12-14-month-
old rTg4510 mice was significantly higher than that in age-matched non-tg mice, 
while the difference in the cerebellum between rTg4510 and non-tg mice or the 
difference between cerebellum and forebrain in rTg4510 mice was not 
significant (Fig. 3E). Because P301L human tau was neither expressed nor 
accumulated in the cerebellum of rTg4510 mice [10, 16], the cerebellum was 
used as a reference region for analyzing the target-to-reference ratio. As a 
result, the mean forebrain-to-cerebellum ratio of AUC at 0-60 min in 12-14-
month-old rTg4510 mice was 9.5% higher than that in age-matched non-tg mice 
(Fig. 3F; AUC ratio ± SEM in 12-14-month-old rTg4510 mice, 1.06±0.0139; AUC 
ratio ± SEM in 12-14-month-old non-tg mice, 0.968±0.0143). In rTg4510 mice, 
the mean AUC ratio increased from 2.5 to 14 months old (Fig. 3G; n=17, r=0.56, 
p=0.022 by Spearman's correlation analysis). Correlation analysis showed that 
the [11C]PBB3 level in the forebrain was correlated with the degree of atrophy in 
the forebrain (Fig. 3H; 2.5-14-month-old rTg4510, n=17, r=-0.73, p=0.0012 by 
Spearman's correlation analysis). It should be noted that the correlation 
between the AUC ratio of [11C]PBB3 in the forebrain and the volume of the 
cerebral cortex disappeared when data from over 7 months old were examined 
(supplemental Fig. 2; 7-14-month-old rTg4510, n=13, r=-0.51, p=0.081 by 
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Spearman's correlation analysis). Since volume reduction of the forebrain was 
concurrent with neuronal loss, it is possible that the disappearance of PBB3-
positive neurons canceled the increase of [11C]PBB3 uptake in aged rTg4510 
mice.  
 
[11C]AC-5216-PET imaging of rTg4510 mice  
PET images of non-tg mice generated by averaging dynamic scan data showed 
that intravenously administered [11C]AC-5216 labeled the cerebellum and brain 
stem (Fig. 4B). In line with the previous study [30], levels of [11C]AC-5216 
signals in the hippocampus and cerebral cortex were lower than those in the 
cerebellum, and the striatum was the lowest region of non-tg brains (Fig. 4B). 
On the other hand, levels of [11C]AC-5216 signals in the hippocampus and 
cerebral cortex of 12-14-month-old rTg4510 mice were higher than those of 
age-matched non-tg mice (Fig. 4A and B). The retention of [11C]AC-5216 in the 
striatum of rTg4510 mice was slightly higher than that in the cerebellum (Fig. 
4A). The TAC of [11C] AC-5216 signals further confirmed higher retention of [11C] 
AC-5216 in the forebrain, hippocampus, cerebral cortex and striatum of 12-14-
month-old rTg4510 mice (n=5) than in the same regions of age-matched non-tg 
mice (n=6) (Fig. 4C and supplemental Fig. 3). Although previous work used the 
striatum as a reference region [30], we had to abandon this method in the 
current study because of the striatal accumulation in rTg4510 mice. In contrast, 
the cerebellum of rTg4510 mice showed a lack of human P301L tau expression 
and a lower level of [11C]AC-5216 signal than other brain regions (Fig. 4A, 4D, 
4E, and supplemental Fig. 3A-D). The brain stem of rTg4510 mice was another 
brain region with less human P301L tau expression, but the TAC in this region 
showed slower clearance of unbound [11C]AC-5216 than that in the cerebellum 
(Fig. 4D and supplemental Fig. 3D). Therefore, the cerebellum was selected as 
reference region to estimate AUC of [11C]AC-5216 signals in the subsequent 
analyses. Similar to [11C]PBB3-PET, AUC of [11C]AC-5216 signals from 0 to 90 
min in forebrain of 12-14-month-old rTg4510 mice was significantly higher than 
those in age-matched non-tg mice (Fig. 4E). The difference in forebrain was 
much greater than the difference in cerebellum (Fig. 4E), with the mean 
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forebrain-to-cerebellum ratio of AUC at 0-90 min in 12-14-month-old rTg4510 
mice being 61% higher than that in age-matched non-tg mice (Fig. 4F; AUC 
ratio ± SEM in 12-14-month-old rTg4510 mice, 1.21±0.0842; AUC ratio ± SEM 
in 12-14-month-old non-tg mice, 0.750±0.0227). This AUC ratio in rTg4510 mice 
continued to increase with age (Fig. 4G; n=17, r=-0.85, p<0.0001 by 
Spearman's correlation analysis). Correlation analysis showed that the [11C]AC-
5216 AUC ratio in the forebrain was negatively correlated with the volume of the 
cerebral cortex (Fig. 4H; n=17, r=-0.83, p<0.0001 by Spearman's correlation 
analysis). 
 
Linkage between tau pathology and microglia activation 
Since both [11C]PBB3 and [11C]AC-5216 levels were significantly correlated with 
age and brain atrophy, we next examined the relationship between [11C]PBB3 
and [11C]AC-5216 levels, and we found a positive correlation (Fig. 5; 2.5-14-
month-old rTg4510, n=17, r=0.54, p =0.028 by Spearman's correlation 
analysis). This correlation was also significant when the age range of 2.5 to 11 
months was selected (Fig. 5; 2.5-11-month-old, n=12, r=0.65, p =0.026 by 
Spearman's correlation analysis). In contrast, the correlation between 
[11C]PBB3 and [11C]AC-5216 signals disappeared when the age range of 7 to 14 
months was chosen, likely due to the saturation of [11C]PBB3 signals in rTg4510 
mice over 7 months of age (Fig. 5; 7-14-month-old, n=13, r=0.033, p =0.92 by 
Spearman's correlation analysis).  
Our previous study and the current data showed that fluorescence labeling with 
PBB3 for brain sections of rTg4510 mice provided evidence of PBB3-binding 
neuronal inclusions in the cerebral cortex and hippocampus of aged rTg4510 
mice (Fig. 6A and 7C) [2]. This evidence strongly supported the viewpoint that in 
vivo [11C]PBB3-PET imaging demonstrated the amount of tau inclusions in living 
brains. On the other hand, the feasibility of [11C]AC-5216 for TSPO was 
examined in detail [35], and [11C]AC-5216-PET imaging most likely expressed 
the amount of TSPO in response to microglial activation (Fig. 6B). To validate 
the in vivo evidence, brain dissection after in vivo imaging followed by 
histochemical analysis was performed. As shown in Figure 6, PBB3-positive 
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neurons were co-labeled with AT8 antibody in the cerebral cortex of 14-month-
old rTg4510 mice, indicating the existence of PBB3-positive 
hyperphosphorylated tau accumulation in neurons (Fig. 6A). On the other hand, 
TSPO immunoreactivity was co-labeled with microglia marker Iba1 antibody but 
not co-localized with AT8-positive neurons (Fig. 6B and C). TSPO signals were 
not overlapped with GFAP signals, suggesting that TSPO was rarely expressed 
in astrocytes (Fig. 6D). Quantitative analysis of PBB3 fluorescence staining 
confirmed the positive correlation between PBB3-positive cell count and the 
AUC ratio of [11C]PBB3 (Table 1 and Fig. 7A; n=8, r=0.81, p=0.022 by 
Spearman's correlation analysis). Similarly, the immunoreactivity of the TSPO 
signal was positively correlated with the AUC ratio of [11C]AC-5216 (Table 1 and 
Fig. 7B; n=8, r=0.90, p=0.0046 by Spearman's correlation analysis). In the non-
tg cerebral cortex, there was no PBB3-labeled inclusion and faint TSPO-positive 
immunoreactivity (Fig. 7A and B). Representative histochemical images showed 
that most of PBB3-positive neurons were co-labeled with AT8 antibody in 
rTg4510 cerebral cortices (Fig. 7C). As confirmed by the correlation analysis, 
mice with more PBB3- and AT8-positive neurons (TG3 and TG4) showed a 
higher level of the AUC ratio of [11C]PBB3 (Fig. 7A). Accumulation of TSPO 
immunoreactivity was observed in two rTg4510 mice (TG4 and TG7) with a 
higher AUC ratio of [11C]AC-5216 (Fig. 7B). Because both TSPO- and microglial 
marker Iba1-positive signals were increased with age and were higher than in 
non-tg mice (Fig. 7D), age-dependent and tau-induced microglial activation was 
evident in rTg4510 mice. Taken together, our data strongly supported the utility 
of [11C]PBB3-PET and [11C]AC-5216 for the in vivo visualization of tau pathology 
and neuroinflammation in rTg4510 mice, respectively. 
 
Discussion 
 In the present study, we demonstrated PET and MRI of transgenic mice 
modeling tauopathy and non-tg controls in order to examine the utility of small-
animal in vivo imaging for pursuing links between tau deposition and 
neurodegeneration. Along with [11C]PBB3, microglial activation was also 
visualized in rTg4510 mice using a radioligand for TSPO, [11C]AC-5216. In 
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rTg4510 mice, tau accumulation, neuroinflammation and neocortical atrophy 
became noticeable at 7 months of age, and retentions of tau and TSPO 
radioligands were inversely correlated to neocortical volumes (Fig. 3 and 4). 
Postmortem immunohistochemical assays revealed that both tau deposition and 
elevated TSPO signals in putative microglia were strongly associated with PET 
signals in the neocortex of rTg4510 mice (Fig. 7). Our results indicate that the 
temporal relationship among tau deposition, neuroinflammation and neuronal 
loss can be pursued by in vivo imaging of animal models.    
 Our [11C]PBB3 PET imaging of rTg4510 mice showed that the 
[11C]PBB3 signal reached a plateau by 7 months of age (Fig. 3G). Previous 
studies using immunohistochemistry and biochemical assays have shown a 
prominent increase and a good correspondence of PBB3 signals with tau levels 
stained by several tau antibodies (e.g., PHF1, Ab39, MC1) and Thioflavin-S in 
the neocortex and hippocampus of rTg4510 mice between 4 and 6 months old 
and that the levels remained stable after 7 months of age [15, 16, 36-38]. This 
age-dependent development of tau pathology was in line with in vivo PBB3 
signals in the current study. We also observed the plateaued tau pathology, 
which showed no significant difference in [11C]PBB3 levels between 7-month-old 
and 12-14-month-old rTg4510 mice. Correlation analysis between [11C]PBB3 
levels and brain atrophy showed no significance in over 7-month-old rTg4510 
mice (Supplemental Fig. 2). The lack of correlation of [11C]PBB3 levels from 
brain atrophy may be due to the disappearance of PBB3-positive inclusions with 
aging. To elucidate this possibility, in vivo two-photon microscopic imaging is 
currently being performed to investigate the progression of tau pathology at 
cellular levels (manuscript in preparation). If longitudinal monitoring can verify 
both production and disappearance of PBB3-positive neurons, the actual 
amount of PBB3-positive tau inclusions may not reflect the total production but 
rather the total in-out balance of tau inclusions. Of interest is the question of 
whether the production rate of PBB3-positive inclusions is strongly associated 
with the severity of neuronal impairments. Further studies in live animals are 
necessary for estimation of the production speed of PBB3-positive inclusions.   
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 Since PBB3 selectively binds to -pleated sheet structures such as 
NFTs, but not to pre-tangles and/or immature tau aggregates, results from 
[11C]PBB3 PET regarding rTg4510 tau pathology likely represent the 
accumulation of NFTs (i.e., mature tau aggregates). Although the abundance of 
NFTs is positively correlated with the severity of cognitive deficits in AD [39, 40], 
accumulating evidence from the study of mechanisms of tau-induced 
neurotoxicity indicated that pre-fibrillar tau aggregates, but not NFTs, might 
cause neuronal dysfunction. Therefore, detection of [11C]PBB3 signal may in 
fact not reflect tau-induced neurotoxicity. However, in combination with 
volumetric MRI and [11C]AC-5216 PET, [11C]PBB3 PET imaging is useful for 
diagnosing neurodegeneration in a mouse model of tauopathy. 
 Inflammation has been suggested as playing a key role in regulating 
both amyloid and tau pathology (reviewed in [41, 42]). Chronic treatment of 
lipopolysaccharide (LPS) in the 3xTg mouse model confirmed that 
neuroinflammatory cytokines and reactive microglia exacerbate the tau 
pathology and contribute to the spreading of tau [43, 44]. According to these 
observations, the development of tau pathology was triggered by increased tau 
phosphorylation. Although tau phosphorylation seems to be essential for NFT 
formation, LPS treatment may not be enough to develop into tau aggregation. 
Likewise, acute LPS administration into rTg4510 mice induced tau 
phosphorylation while tau aggregation was not affected [45]. In the present 
study, elevated [11C]AC-5216 signals in the forebrain of rTg4510 mice appeared 
at 7 months of age (Fig. 4E). Neither Iba1 nor TSPO-labeled microglia were 
accumulated in younger rTg4510 mice. Since intraneuronal inclusions labeled 
by tau oligomer-specific antibody appeared as early as at 1.5 months of age 
[38], neuroinflammatory response may be downstream of the formation of 
pathological tau aggregates. However, it is still unclear whether microglial 
activation already occurs before pathological tau accumulation, as this depends 
on the sensitivity and specificity of both Iba1 and TSPO antibodies for detecting 
activated microglia. In contrast to the investigation of inflammatory mechanisms 
against tau pathology, it has been reported that non-steroidal anti-inflammatory 
 16 
drugs (NSAIDs) such as -secretase modulators influenced the A population. 
Epidemiological studies have demonstrated a link between the use of anti-
inflammatory drugs and the prevalence of AD [46]. Therefore, the induction of 
pro-inflammatory mediators likely exacerbates the A pathology [47]. 
Conversely, the activation of glial cells can stimulate clearance of A plaques 
via the induction of phagocytosis [48]. This would be feasible if the 
pathogenesis of tau protein is associated with such dual functions of 
neuroinflammation. Microglial phagocytosis of tau aggregates similar to the 
clearance of A plaques should be confirmed by examination of in vivo 
fluorescence microscopic imaging, awaiting only the development of a specific 
fluorescent labeling for microglial cells.  
The recent development of A and tau PET ligands will assist in 
advanced clinical diagnosis of AD. As the next step, early pathological 
biomarkers will prove essential for effective therapeutic intervention. Since 
current tau PET tracers have a limitation regarding the detection of pre-fibrillar 
tau aggregates, novel ligands that potentially recognize pre-fibrillar and/or 
intermediate aggregated species of tau need to be developed. In fact, our 
previous study showed that tau oligomer-specific antibody TOC1-positive 
inclusions preceded PBB3-positive signals using double-fluorescence staining 
of rTg4510 brain sections [38]. Therefore, the conformation of TOC-1-positive 
tau likely takes place before PBB3-positive -sheet-rich structures, although this 
remains inconclusive in terms of -sheet specific amyloid tracers in their 
detection of amyloid oligomers/protofibrils [49]. Because several groups have 
identified unique chemical compounds that preferentially bind to intermediate 
aggregates of A and tau [50-54], those compounds might represent more 
suitable ligands for the early detection of AD pathology.   
 In conclusion, the utilities of [11C]PBB3 and [11C]AC-5216 for evaluating 
disease progression in living tauopathy brains were confirmed by in vivo 
imaging of a tauopathy mouse model. The time-course of in vivo imaging 
indicates that the elevated TSPO signal is induced by tau deposition and 
correlates well with brain atrophy. Our system allows us to non-invasively 
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examine the mechanisms underlying both tau-induced neurodegeneration and 
neuroinflammation. 
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Figure legends 
 
Fig. 1 Anatomical localization of volumes of interest (VOIs). 
Horizontal (A), sagittal (B), and coronal (C-E) T2W MRI slices of the mouse 
brain showed six structures: cerebral cortex (CTX), hippocampus (HIP), 
striatum (STR), cerebellum (CER), brain stem (BS) and forebrain (FB, labeled 
by red color). The level of the sagittal slice (B) is indicated as a-p line in the 
horizontal slice (A). Three levels of coronal slices (C-E) are indicated as sagittal 
sections (1-3). Illustrated brain regions of CER and FB were used for PET 
quantification. Orientations of slice are indicated as 'a' (anterior), 'p' (posterior), 
R (right) and L (left). 
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Fig. 2 T2-weighted MRI-based brain volumes of non-tg and rTg4510 mice. 
A. Representative MR images of 13-month-old non-tg, 7-month-old and 13-
month-old rTg4510 mouse brains with coronal, sagittal and horizontal slices. 
Brain regions of cerebral cortex (CTX), hippocampus (HIP), striatum (STR), 
cerebellum (CER), and brain stem (BS) are labeled in the sagittal slice of non-tg 
mice. Orientations of slice are indicated as 'a' (anterior), 'p' (posterior), R (right) 
and L (left). B-G. Brain volumes of cerebral cortex (B), forebrain (C), 
hippocampus (D), brain stem (E), striatum (F) and cerebellum (G) from 2.5-
month-old non-tg (n=3), 12-14-month-old non-tg (n=6), 2.5-4-month-old (n=4), 
7-month-old (n=3), 10-11-month-old (n=5), and 12-14-month-old (n=5) rTg4510 
mice. Values are mean ± standard error. 
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Fig. 3 Accumulation of [11C]PBB3 signals in rTg4510 mouse brains. 
A and B. Orthogonal views of [11C]PBB3 PET images in brains of 13-month-old 
rTg4510 (A) and 13-month-old non-tg (B) mice generated by averaging dynamic 
scan data at 0-60 min after intravenous injection of [11C]PBB3. Images indicated 
as horizontal (upper left), sagittal (upper right), dorsal hippocampal level of 
coronal (left), ventral hippocampal level of coronal (middle) and cerebellum level 
of coronal (right) slices. Brain regions of cerebral cortex (CTX), hippocampus 
(HIP), striatum (STR), cerebellum (CER), and brain stem (BS) are labeled in the 
sagittal slice. Orientations of slice are indicated as 'a' (anterior), 'p' (posterior), R 
(right) and L (left). C and D. Time-radioactivity curves in the forebrain (C) and 
cerebellum (D) in 12-14-month-old non-tg (blue triangles, n=6) and rTg4510 
(red squares, n=5) mice. Error bars represent SEM. The difference in the 
forebrain between rTg4510 and non-tg was significant (interaction p value 
<0.0001 by two-way ANOVA), but not in the cerebellum (interaction p 
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value=0.96 by two-way ANOVA). E. Mean AUC at 2-30 min in the forebrain or 
the cerebellum of 12-14-month-old non-tg (open columns, n=6) and rTg4510 
(filled columns, n=5) from dynamic PET scans. Error bars represent SEM. Mean 
AUC in the forebrain of rTg4510 mice was significantly higher than that in the 
forebrain of non-tg mice (*p<0.05 by independent t-test), whereas the difference 
in the cerebellum was not significant. F. AUC ratio (forebrain to cerebellum) at 0-
60 min of 12-14-month-old rTg4510 (filled columns, n=5) and non-tg (open 
columns, n=6). Error bars represent SEM. AUC ratio of rTg4510 mice was 
significantly higher than that of non-tg mice (**p<0.01) G. Scatterplot of AUC 
ratio (forebrain to cerebellum) for [11C]PBB3 against age (months) of rTg4510 
mice (n=17). H. Scatterplot of AUC ratio (forebrain to cerebellum) for [11C]PBB3 
against neocortical volume (cm3) of rTg4510 mice (n=17). 
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Fig. 4 Progression of microglial activation visualized by [11C]AC-5216 PET 
imaging in rTg4510 mouse brains. 
A and B. Orthogonal views of TSPO distribution in brains of 13-month-old 
rTg4510 (A) and 13-month-old non-tg (B) mice generated by averaging dynamic 
scan data at 0-90 min after intravenous injection of [11C]AC-5216. Images 
indicated as horizontal (upper left), sagittal (upper right), dorsal hippocampal 
level of coronal (left), ventral hippocampal level of coronal (middle) and 
cerebellum level of coronal (right) slices. Brain regions, cerebral cortex (CTX), 
hippocampus (HIP), striatum (STR), cerebellum (CER), brain stem (BS) are 
labeled in the sagittal slice. Orientations of slice are indicated as 'a' (anterior), 'p' 
(posterior), R (right) and L (left). C and D. Time-radioactivity curves in the 
forebrain (C) and cerebellum (D) in 12-14-month-old non-tg (blue triangles, n=6) 
and rTg4510 (red squares, n=5) mice. Error bars represent SEM. The 
differences in the forebrain and cerebellum between rTg4510 and non-tg were 
significant (interaction p value <0.0001 by two-way ANOVA). E. Mean AUC at 0-
90 min in the forebrain or the cerebellum of 12-14-month-old non-tg (open 
columns, n=6) and rTg4510 (filled columns, n=5) from dynamic PET scans. 
Error bars represent SEM. Mean AUC in rTg4510 mice was significantly higher 
than that in non-tg mice (***p<0.001 by independent t-test for the forebrain, 
**p<0.01 by independent t-test for the cerebellum). F. AUC ratio (forebrain to 
cerebellum) at 0-90 min of 12-14-month-old rTg4510 (filled columns, n=5) and 
non-tg (open columns, n=6). Error bars represent SEM. AUC ratio of rTg4510 
mice was significantly higher than that of non-tg mice (**p<0.01) G. Scatterplot 
of AUC ratio (forebrain to cerebellum) for [11C]AC-5216 against age (months) of 
rTg4510 mice (n=17). H. Scatterplot of AUC ratio (forebrain to cerebellum) for 
[11C]AC-5216 against neocortical volume (cm3) of rTg4510 mice (n=17). 
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Fig. 5 Correlation between [11C]AC-5216 and [11C]PBB3 signals in forebrains of 
rTg4510 mice. 
A. Scatterplot of AUC ratio (forebrain to cerebellum) for [11C]AC-5216 of 
rTg4510 mice against AUC ratio (forebrain to cerebellum) for [11C]PBB3. 2.5-4-
month-old (n=4, squares), 7-11-month-old (n=8, triangles) and 12-14-month-old 
(n=5, circles) rTg4510 mice were presented in the plot. B. Statistical data 
showing the correlation between [11C]AC-5216 and [11C]PBB3 signals. 
Spearman's correlation analysis was performed. Significant correlation was 
found: *p<0.05.  
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Fig. 6 PBB3 fluorescence labeling and immunohistochemistry. 
Sagittal serial sections of 14-month-old rTg4510 mouse were labeled with PBB3 
and several antibodies. A. Representative image of co-labeling with PBB3 
(green) and AT8 (red) antibody in cerebral cortex of rTg4510 mice. Image of 
PBB3 labeling was captured by Leica fluorescence microscope. Image-captured 
section was re-labeled with AT8 antibody, and then the identical field was 
captured with red fluorescence filter. Scale bars = 50 m and 10 m (inset). B. 
Representative image of double-staining with TSPO (green) and Iba (red) 
antibodies in cerebral cortex of rTg4510 mice. C. Representative image of 
double-staining with TSPO (green) and AT8 (red) antibodies in cerebral cortex 
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of rTg4510 mice. D. Representative image of double-staining with TSPO 
(green) and GFAP (red) antibodies in cerebral cortex of rTg4510 mice. Images 
of B-D were captured by Keyence microscope. Scale bars = 50 m and 10 m 
(inbox). 
 
 
Fig. 7 Correlation between histology and PET 
A. Scatterplot of PBB3-positive cell numbers in cerebral cortices of rTg4510 and 
non-tg mice (n=8, squares, TG1-TG8; n=4, triangles, NT1-NT4 listed in Table 1) 
against AUC ratio (forebrain to cerebellum) for [11C]PBB3. PBB3-positive cell 
numbers were averaged in five fields of PBB3 fluorescence-labeled images (0.3 
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mm x 0.4 mm). B. Scatterplot of TSPO immunoreactivities in forebrains of 
rTg4510 and non-tg mice (n=8, squares, TG1-TG8; n=4, triangles, NT1-NT4 
listed in Table 1) against AUC ratio (forebrain to cerebellum) for [11C]AC-5216. 
Immunoreactivity was presented as a signal ratio (%) in total area (2.5 mm2 field 
of forebrain region). C. Representative images of co-labeling with PBB3 (green) 
and AT8 (red) antibody in cerebral cortices of 9-month-old non-tg, 8-month-old 
(TG1), 10.5-month-old (TG3 and TG4) and 11-month-old (TG7) rTg4510 mice. 
Images were captured by Leica fluorescence microscope. Scale bars = 20 m. 
D. Representative images of immunohistochemistry. Cerebral cortices in sagittal 
serial sections of 9-month-old non-tg, 8-month-old (TG1), 10.5-month-old (TG3 
and TG4) and 11-month-old (TG7) rTg4510 mice were labeled with Iba1 (red) 
and TSPO (red) antibodies. Images were captured by Keyence microscope. 
Scale bar = 20 m. 
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Supplemental Figure 1 
Time-radioactivity curves of [11C]PBB3 signals in the cerebral cortex (A), 
hippocampus (B), striatum (C) and brain stem (D) in 12-14-month-old non-tg 
(blue triangles, n=6) and rTg4510 (red squares, n=5) mice. Y-axis indicates 
percent of injection dose per unit volume (%ID/ml). Error bars represent SEM. 
E. Statistical data showing the difference between rTg4510 and non-tg mice. 
Two-way ANOVA was performed. Significant interaction was found: 
****p<0.0001, ***p<0.001, **p<0.01. 
 
Supplemental Figure 2 
Correlation between AUC ratio (forebrain to cerebellum) for [11C]PBB3 and 
neocortical volume of rTg4510 mice. A. Scatterplot of AUC ratio (forebrain to 
cerebellum) for [11C]PBB3 against neocortical volume (cm3) of rTg4510 mice. 
2.5-4-month-old (n=4, squares) and 7-14-month-old (n=13, triangles) rTg4510 
mice are presented in the plot. B. Statistical data showing the correlation 
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between [11C]PBB3 signal and cortical volume. Spearman's correlation analysis 
was performed. Significant correlation was found: **p<0.01.  
 
Supplemental figure 3 
Time-radioactivity curves of [11C]AC-5216 signals in the cerebral cortex (A), 
hippocampus (B), striatum (C) and brain stem (D) in 12-14-month-old non-tg 
(blue triangles, n=6) and rTg4510 (red squares, n=5) mice. Y-axis indicates 
percent of injection dose per unit volume (%ID/ml). Error bars represent SEM. 
E. Statistical data showing the difference between rTg4510 and non-tg mice. 
Two-way ANOVA was performed. Significant interaction was found: 
****p<0.0001. 
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